Jefferies Group reissued their hold rating on shares of Catalent Inc (NASDAQ:CTLT) in a report released on Thursday. The brokerage currently has a $28.00 price target on the stock, up from their previous price target of $25.00.
A number of other brokerages also recently weighed in on CTLT. Morgan Stanley reiterated a hold rating on shares of Catalent in a report on Tuesday, August 30th. Piper Jaffray Cos. reiterated an overweight rating and issued a $30.00 target price (down from $30.50) on shares of Catalent in a report on Tuesday, August 30th. TheStreet upgraded Catalent from a sell rating to a hold rating in a report on Wednesday, August 17th. Zacks Investment Research downgraded Catalent from a hold rating to a strong sell rating in a report on Monday, August 15th. Finally, Wells Fargo & Co. upgraded Catalent from a market perform rating to an outperform rating in a report on Tuesday, June 21st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average target price of $28.67.
Shares of Catalent (NASDAQ:CTLT) opened at 25.94 on Thursday. The stock has a 50 day moving average price of $25.29 and a 200 day moving average price of $25.67. Catalent has a 12-month low of $18.92 and a 12-month high of $32.24. The firm has a market cap of $3.24 billion and a P/E ratio of 29.15.
Catalent (NASDAQ:CTLT) last issued its earnings results on Monday, August 29th. The company reported $0.52 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.53 by $0.01. The business earned $532.20 million during the quarter. The business’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.61 earnings per share. On average, equities analysts expect that Catalent will post $1.40 earnings per share for the current year.
In other news, major shareholder Blackstone Management Associat sold 17,100,705 shares of the business’s stock in a transaction that occurred on Friday, September 9th. The stock was sold at an average price of $23.58, for a total transaction of $403,234,623.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Several large investors have recently added to or reduced their stakes in CTLT. Commerzbank Aktiengesellschaft FI increased its stake in Catalent by 75.3% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 37,894 shares of the company’s stock valued at $871,000 after buying an additional 16,273 shares in the last quarter. California State Teachers Retirement System increased its stake in Catalent by 17.8% in the second quarter. California State Teachers Retirement System now owns 209,227 shares of the company’s stock valued at $4,810,000 after buying an additional 31,570 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Catalent by 6.5% in the second quarter. Bank of New York Mellon Corp now owns 1,202,407 shares of the company’s stock valued at $27,644,000 after buying an additional 73,250 shares in the last quarter. Kornitzer Capital Management Inc. KS purchased a new stake in Catalent during the second quarter valued at approximately $4,582,000. Finally, ING Groep NV purchased a new stake in Catalent during the second quarter valued at approximately $690,000.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.